COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
Journal
JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
3
9
2021
medline:
12
1
2022
entrez:
2
9
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has had consequences for patients with cancer worldwide and has been associated with delays in diagnosis, interruption of treatment and follow-up care, and increases in overall infection rates and premature mortality. Despite the challenges experienced during the pandemic, the global oncology community has responded with an unprecedented level of investigation, collaboration, and technological innovation through the rapid development of COVID-19 registries that have allowed an increased understanding of the natural history, risk factors, and outcomes of patients with cancer who are diagnosed with COVID-19. This review describes 14 major registries comprising more than 28 500 patients with cancer and COVID-19; these ongoing registry efforts have provided an improved understanding of the impact and outcomes of COVID-19 among patients with cancer. An initiative is needed to promote active collaboration between different registries to improve the quality and consistency of information. Well-designed prospective and randomized clinical trials are needed to collect high-level evidence to guide long-term epidemiologic, behavioral, and clinical decision-making for this and future pandemics.
Identifiants
pubmed: 34473192
pii: 2783489
doi: 10.1001/jamaoncol.2021.4083
pmc: PMC8805603
mid: NIHMS1771717
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1882-1890Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Références
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Blood Adv. 2020 Dec 8;4(23):5966-5975
pubmed: 33278301
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet. 2020 Oct 10;396(10257):1067-1068
pubmed: 33038964
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Cancer Discov. 2020 Oct;10(10):1514-1527
pubmed: 32699031
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Cancer Invest. 2021 Mar;39(3):205-213
pubmed: 33534645
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
JAMA Oncol. 2021 Feb 1;7(2):227-229
pubmed: 33300955
Ann Rheum Dis. 2020 Sep;79(9):1143-1151
pubmed: 32719045
Semin Radiat Oncol. 2019 Oct;29(4):354-361
pubmed: 31472738
Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):354-362
pubmed: 33053024
Eur J Cancer. 2021 Jun;150:190-202
pubmed: 33932726
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Blood. 2020 Jul 2;136(1):137-139
pubmed: 32457999
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
Cancer. 2021 May 1;127(9):1459-1468
pubmed: 33378122
JAMA Oncol. 2021 Feb 1;7(2):171-172
pubmed: 33300984
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33753569
Eur J Cancer. 2020 Dec;141:171-184
pubmed: 33161241
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650523
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Blood. 2020 Dec 24;136(26):3033-3040
pubmed: 33367546
JAMA. 2020 Oct 6;324(13):1298-1306
pubmed: 32876689
Nat Cancer. 2020;1(5):473-476
pubmed: 32346676
Cancer Cell. 2020 Nov 9;38(5):605-608
pubmed: 33098754
J Clin Invest. 2020 Dec 1;130(12):6417-6428
pubmed: 33141117
Cancer Invest. 2020 Nov;38(10):537-542
pubmed: 33090883